Kommentar
Fluvoxamine vs Placebo and Time to Recovery in Outpatients With Mild to Moderate COVID-19
JAMA · 2023
DOI: 10.1001/jama.2023.5061 ↗Kurz gefasst
Kommentar in der Zeitschrift JAMA, 2023. Verfasst von Sahar Ashraf und 1 weiteren Autor:innen. Beteiligte Einrichtung: Northpointe Psychiatry, Lewisville, Texas. Hauptthemen laut MEDLINE: Antiviral Agents, COVID-19, COVID-19 Drug Treatment, Fluvoxamine. Die Arbeit nennt 2 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Antiviral AgentsCOVID-19COVID-19 Drug TreatmentFluvoxamineHumansDouble-Blind MethodTime FactorsRecovery of Function
Substanzen
Antiviral AgentsFluvoxamine
Autor:innen und Institutionen
- Northpointe Psychiatry, Lewisville, Texas.
- Kansas City University, Ozark Center, Joplin, Missouri.
Zitieren
APA
Ashraf, S., & Ashraf, N. (2023). Fluvoxamine vs Placebo and Time to Recovery in Outpatients With Mild to Moderate COVID-19. JAMA. https://doi.org/10.1001/jama.2023.5061
Vancouver
Ashraf S, Ashraf N. Fluvoxamine vs Placebo and Time to Recovery in Outpatients With Mild to Moderate COVID-19. JAMA. 2023. doi:10.1001/jama.2023.5061
BibTeX
@article{Ashraf2023,
author = {Ashraf, Sahar and Ashraf, Nauman},
title = {Fluvoxamine vs Placebo and Time to Recovery in Outpatients With Mild to Moderate COVID-19},
journal = {JAMA},
year = {2023},
doi = {10.1001/jama.2023.5061}
}
EUVIMED